IVVD - Invivyd EV/EBITDA Multiple

Corporate company logo of Invivyd Inc (IVVD)

This chart of EV/EBITDA valuation history serves as an indicator for Invivyd, Inc. (IVVD), which develops protective antibodies against mutating viruses by adapting technologies to new strains to minimize risks. The current metric stands at 0.00. The business relies on high profitability, with primary costs concentrated in R&D, enabling the cost-effective global scaling of approved treatments.

IVVD Invivyd Corp: Business Value to Operating Income Before Depreciation in the range 11/23/2025 - 11/10/2026
Original product of invivyd.com

Invivyd, Inc. (IVVD) focuses on developing antiviral antibodies, utilizing grants and commercial sales to fund its research and development. The current EV/EBITDA multiple for this capital-intensive enterprise stands at 0.00, benchmarking enterprise value against operating income. This metric accounts for net debt, determining the real value of the business relative to its ability to generate profit. Low values here either indicate an undervalued asset or a critical risk of insolvency.

Competitor analysis for Invivyd, Inc.

Gilead Sciences Inc - Enterprise Value to EBITDA Ratio|Cidara - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Novavax, Inc. - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio curevac.com CVAC|Valneva (VALN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Vir Biotechnology Inc - Business Value to Operating Income Before Depreciation|Enterprise Value to EBITDA Ratio SIGA|EV/EBITDA Multiple Emergent Bio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Atea Pharmaceuticals (AVIR)|Total Company Value to Operating Income Before Depreciation Ratio enanta.com|EV/EBITDA Multiple INO (Inovio)|Total Company Value to Operating Income Before Depreciation Ratio HilleVax Inc (HLVX)|KLRS - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|DYAI (Dyadic International) - Enterprise Value to Operating Income Before Depreciation|NNVC (nanoviricides.com) - Enterprise Value to EBITDA Ratio|TLPH (talphera.com) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|COCP (Cocrystal Pharma) - EV/EBITDA Multiple|Traws Therapeutics (TRAW) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio DWTX (Dogwood Therapeutics, Inc.)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization QLGN (Qualigen Corp)|AlloVir - Enterprise Value to EBITDA Ratio|VBI Vaccines, Inc. (VBIV) - Company Value to EBITDA|Virios - EV/EBITDA Multiple|VXRT (Vaxart, Inc.) - Enterprise Value to Operating Income Before Depreciation